THE ANALIZA VARIJABILNOSTI L1 GENA HUMANOG PAPILOMA VIRUSA TIPA 16 U NAŠOJ POPULACIJI

  • Filip Milošević Institut za mikrobiologiju i imunologiju, Medicinski fakultet Univerziteta u Beogradu, Beograd
  • Nina Gatarić Univerzitet u Beogradu, Medicinski fakultet, Institut za fiziologiju "Rihard Burijan", Beograd, Srbija
  • prof. dr Aleksandra Knežević Institut za mikrobiologiju i imunologiju, Medicinski fakultet Univerziteta u Beogradu
Ključne reči: Humani papiloma virus, HPV16, L1 gen, filogenetska analiza

Sažetak


Uvod: Humani papiloma virusi (HPV) prepoznati su kao glavni etiološki faktor u patogenezi karcinoma grlića materice. Najveći medicinski značaj ima visokorizični tip HPV16. Na osnovu razlika u nukleotidnoj sekvenci genoma tipa 16 pokazano je postojanje 16 varijanti ovog tipa sa različitom geografskom distribucijom.

Cilj rada: Ispitivanje varijabilnosti nukleotidne sekvence L1 gena HPV16 varijanti zastupljenih u našem području.

Materijal i metode: U rad je uključeno 37 sekvenci L1 gena HPV16 preuzetih iz baze podataka Instituta za mikrobiologiju i imunologiju Medicinskog fakulteta Univerziteta u Beogradu. Sekvence su poređene sa referentnim sekvencama varijanti HPV16 i konstrukcija filogenetskog stabla je urađena primenom MEGA (Molecular Evolutionary Genetics Analysis, verzija X) softverskog paketa.

Rezultati: Od 37 analiziranih sekvenci HPV16 L1 gena, 23 se grupišu uz evropske varijante. Ostali izolati se grupišu uz ne-evropske HPV16 varijante. Nukleotidna distanca je bila manja od 1%, odnosno na nivou podvarijanti.

Zaključak: Rezultati ove studije ukazuju da su u našoj populaciji najzastupljenije evropske varijante HPV16 virusa, ali ukazuju i na prisustvo ne-evropskih varijanti. Dalja analiza je neophodna u cilju praćenja cirkulacije HPV16 varijanti u našoj populaciji.

Ključne reči: Humani papiloma virus, HPV16, L1 gen, filogenetska analiza

Reference


  1. Knežević A, 2019. Medicinska mikrobiologija. 1st ed. Beograd: Medicinski fakultet Univerziteta u Beogradu, pp.513-518.

  2. Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses. 2015;7(7):3863-3890.

  3. Boulet G, Horvath C, Broeck D, Sahebali S, Bogers J. Human papillomavirus: E6 and E7 oncogenes. The International Journal of Biochemistry & Cell Biology. 2007;39(11):2006-2011.

  4. Forman D, de Martel C, Lacey C, Soerjomataram I, Lortet-Tieulent J, Bruni L et al. Global Burden of Human Papillomavirus and Related Diseases. Vaccine. 2012;30:F12-F23.

  5. Chesson H, Ekwueme D, Saraiya M, Dunne E, Markowitz L. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443-8450.

  6. Winer R, Feng Q, Hughes J, O’Reilly S, Kiviat N, Koutsky L. Risk of Female Human Papillomavirus Acquisition Associated with First Male Sex Partner. The Journal of Infectious Diseases. 2008;197(2):279-282.

  7. Mühr L, Eklund C, Dillner J. Towards quality and order in human papillomavirus research. Virology. 2018;519:74-76.

  8. de Villiers E. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1-2):2-10.

  9. zur Hausen H. Papillomaviruses in the causation of human cancers — a brief historical account. Virology. 2009;384(2):260-265.

  10. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F et al. A review of human carcinogens—Part B: biological agents. The Lancet Oncology. 2009;10(4):321-322.

  11. Serrano B, Brotons M, Bosch F, Bruni L. Epidemiology and burden of HPV-related disease. Best Practice & Research Clinical Obstetrics & Gynaecology. 2018;47:14-26.

  12. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer. 2017;141(4):664-670.

  13. 13. Bello B, Spinillo A, Alberizzi P, Cesari S, Gardella B, D'Ambrosio G et al. Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions. Journal of Medical Virology. 2009;81(4):703-712.

  14. Bosch F, Manos M, Munoz N, Sherman M, Jansen A, Peto J et al. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective. JNCI Journal of the National Cancer Institute. 1995;87(11):796-802.

  15. Li N, Franceschi S, Howell-Jones R, Snijders P, Clifford G. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. International Journal of Cancer. 2010;128(4):927-935.

  16. Zehender G, Frati E, Martinelli M, Bianchi S, Amendola A, Ebranati E et al. Dating the origin and dispersal of Human Papillomavirus type 16 on the basis of ancestral human migrations. Infection, Genetics and Evolution. 2016;39:258-264.

  17. de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet Oncology. 2010;11(11):1048-1056.

  18. Bernard H, Burk R, Chen Z, van Doorslaer K, Hausen H, de Villiers E. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70-79.

  19. Burk R, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013;445(1-2):232-243.

  20. Mirabello L, Clarke M, Nelson C, Dean M, Wentzensen N, Yeager M et al. The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated Carcinogenesis. Viruses. 2018;10(2):80.

  21. Cornet I, Gheit T, Iannacone M, Vignat J, Sylla B, Del Mistro A et al. HPV16 genetic variation and the development of cervical cancer worldwide. British Journal of Cancer. 2012;108(1):240-244.

  22. Cornet I, Gheit T, Franceschi S, Vignat J, Burk R, Sylla B et al. Human Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR. Journal of Virology. 2012;86(12):6855-6861.

  23. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2014;136(5):E359-E386.

  24. Park J, Shin S, Kim E, Kim J, Kim Y, Oh S et al. Association of human papillomavirus type 16 and its genetic variants with cervical lesion in Korea. APMIS. 2016;124(11):950-957.

  25. Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R, Rodriguez A et al. Human Papillomavirus Type 16 Variants and Risk of Cervical Cancer. JNCI Journal of the National Cancer Institute. 2001;93(4):315-318.

  26. Rader J, Tsaih S, Fullin D, Murray M, Iden M, Zimmermann M et al. Genetic variations in human papillomavirus and cervical cancer outcomes. International Journal of Cancer. 2019;144(9):2206-2214.

  27. Clifford G, Tenet V, Georges D, Alemany L, Pavón M, Chen Z et al. Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Research. 2019;7:67-74.

  28. Bernard H. Coevolution of papiliomaviruses with human populations. Trends in Microbiology. 1994;2(4):140-143.

  29. Kovačević G, Milošević V, Knežević P, Knežević A, Knežević I, Radovanov J et al. Prevalence of oncogenic Human papillomavirus and genetic diversity in the L1 gene of HPV16 HPV 18 HPV31 and HPV33 found in women from Vojvodina Province Serbia. Biologicals. 2019;58:57-63.

  30. Jendoubi-Ferchichi M, Satouri L, Ghoul F, Malek-Mellouli M, Derbal A, Makni M et al. Phylogeny and Classification of Human Papillomavirus (HPV)16 and HPV18 Variants Based on E6 and L1 genes in Tunisian Women with Cervical Lesions. Asian Pacific Journal of Cancer Prevention. 2018;19(12):3361-3366.

Objavljeno
2023/02/06
Broj časopisa
Vol. 73 Br. 4 (2022): Medicinski podmladak
Rubrika
Originalni naučni članak